Plasma cannabinoid pharmacokinetics following controlled oral Δ 9-tetrahydrocannabinol and oromucosal cannabis extract administration

Clinical Chemistry

Volumn 57, Issue 1, 2011, Pages 66-75

  Karschner, Erin L ^a   Darwin, W David ^a   Goodwin, Robert S ^a   Wright, Stephen ^b   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Porton Down Science Park   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11 HYDROXY TETRAHYDROCANNABINOL; 11 NOR 9 CARBOXY TETRAHYDROCANNABINOL; CANNABIS; DRONABINOL; PLACEBO; TETRAHYDROCANNABINOL DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MASS FRAGMENTOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SMOKING; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CANNABIDIOL; CANNABIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MOUTH MUCOSA; PLANT EXTRACTS; TETRAHYDROCANNABINOL; YOUNG ADULT;

CANNABIS;

EID: 78650968528     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.152439     Document Type: Article

References (29)

1. US Food and Drug Administration. Inter-agency advisory regarding claims that smoked marijuana is a medicine. Rockville (MD): Department of Health and Human Services; 2006. Available at: Http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/2006/ucm108643.htm.
2. Watson SJ, Benson JA Jr, Joy JE. Marijuana and medicine: Assessing the science base: A summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry 2000;57:547-52.
3. GW Pharmaceuticals. Sativex receives qualifying notice for approval in Canada for the relief of cancer pain [Press Release]. 2007. Available at: Http://www. gwpharm.com/relief%20of%20Cancer%20Pain.aspx.
4. GW Pharmaceuticals. GW announces UK launch of world's first prescription cannabis medicine [Press Release]. 2010. Available at: Http:// www.gwpharm.com/release-sativex-launch.aspx.
5. Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB. Influence of cannabidiol on delta-9- tetrahydrocannabinol effects. Clin Pharmacol Ther 1976;19:300-9.
6. McPartland JM, Russo EB. Cannabis and cannabis extracts: Greater than the sum of their parts? J Cannabis Ther 2001;1:103-32.
7. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9- tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980;28: 409-16.
8. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Single dose kinetics of deuterium labelled delta-1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Environ Mass Spectrom 1982;9:6-10.
9. Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE. Single-dose kinetics of deuterium-labelled cannabidol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 1986;13:77-83.
10. Guy GW, Robson P. A phase I, open label, fourway crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on 3 difference areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers. J Cannabis Ther 2003;3:79-120.
11. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-) delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998;95:8268-73.
12. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995;56:485-6.
13. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 1974;28:172-7.
14. McArdle K, Mackie P, Pertwee R, Guy G, Whittle B, Hawksworth G. Selective inhibition of delta-9- tetrahydrocannabinol metabolite formation by cannabidiol in vitro [Abstract]. Toxicology 2001; 168:133-4. Proceedings of the BTS Annual Congress.
15. Hunt CA, Jones RT, Herning RI, Bachman J. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet Biopharm 1981;9:245-60.
16. Bornheim LM, Correia MA. Purification and characterization of the major hepatic cannabinoid hydroxylase in the mouse: A possible member of the cytochrome P-450IIC subfamily. Mol Pharmacol 1991;40:228-34.
17. Bornheim LM, Grillo MP. Characterization of cytochrome P450 3A inactivation by cannabidiolhydrozyquinone as a P450 inactivator. Chem Res Toxicol 1998;11:1209-16.
18. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: Depression is a major confounding factor. Diabetes Care 2010;33:128-30.
19. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial. Pain 2004;112:299-306.
20. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Multiple Sclerosis 2006;12:639-45.
21. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis 2004;10:425-33.
22. Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: A pilot study. J Glaucoma 2006;15:349-53.
23. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006;45:50-2.
24. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebocontrolled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancerrelated pain. J Pain Symptom Manage 2010;39: 167-79.
25. Karschner E, Barnes A, Lowe R, Scheidweiler K, Huestis M. Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Delta (9)-tetrahydrocannabinol (THC), 11- hydroxy-THC, and 11-nor-9-carboxy-THC in plasma. Anal Bioanal Chem 2010;397:603-11.
26. Guy GW, Robson PJ. A phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK0215). J Cannabis Ther 2004;3: 121-52.
27. Barnes MP. Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006;7:607-15.
28. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids, I: Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992;16: 276-82.
29. Wall ME, Sadler BM, Brine D, Taylor H, Perez- Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983;34: 352-63.